BAP1 Mutations in Melanoma Susceptibility Patients in Spain

被引：0
|
作者：
Potrony, M. [1 ]
Puig-Butille J, A. [2 ]
Aguilera, P. [3 ]
Tell, G. [1 ]
Azon-Masoliver, A.
Carrera, C. [4 ]
Badenas, C. [2 ]
Malvehy, J. [4 ]
Puig, S. [4 ]
机构：
[1] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, CIBER Enfermedades Raras,Inst Salud Carlos 3,Mela, E-08007 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS,Bio, CIBER Enfermedades Raras,Inst Salud Carlos 3,Mela, E-08007 Barcelona, Spain
[3] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS,Pho, CIBER Enfermedades Raras,Inst Salud Carlos 3,Derm, E-08007 Barcelona, Spain
[4] Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS,Mel, CIBER Enfermedades Raras,Inst Salud Carlos 3,Derm, E-08007 Barcelona, Spain
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [41] Prevalence of germline BAP1 mutations in patients with malignant mesothelioma (MM)
    Hellmann, Matthew David
    Borsu, Laetitia
    Zehir, Ahmet
    Cheng, Donavan T.
    Zha, Zheng
    Siegel, Beth
    Rohrer, Rebecca W.
    Robson, Mark E.
    Arnold, Angela G.
    Fleischut, Megan Harian
    Cavatore, Magali
    Gaskeil, Alice A.
    Gawel, Craig
    Robertson, Alexander
    Viale, Agnes
    Rusch, Valerie W.
    Krug, Lee M.
    Ladanyi, Marc
    Zauderer, Marjorie Glass
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] BAP1 mutations in mesothelioma: advances and controversies
    Sneddon, Sophie
    Creaney, Jenette
    CURRENT PULMONOLOGY REPORTS, 2016, 5 (01) : 13 - 19
  • [43] A spectrum of BAP1 expression from naevus to melanoma in a patient with BAP1 tumour predisposition syndrome
    Ogura, Yasuaki
    Shimauchi, Takatoshi
    Sugiyama, Tomoko
    Sugimura, Yuki
    Nakagawa, Masahiro
    Osawa, Harumo
    Kojima, Risa
    Iwaizumi, Moriya
    Honda, Tetsuya
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2025,
  • [44] Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma
    K. G. Ewens
    E. Lalonde
    J. Richards-Yutz
    C. L. Shields
    A. Ganguly
    BMC Cancer, 18
  • [45] Exploiting ferroptosis in mutant BAP1 uveal melanoma
    Cunanan, Camille J.
    CANCER RESEARCH, 2023, 83 (07)
  • [46] The role of BAP1 loss of function in uveal melanoma
    Brooks, K.
    Dhomen, N.
    Marais, R.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S60 - S61
  • [47] Uveal melanoma and BAP1 tumour predisposition syndrome
    Luyten, G. P. M.
    Chau, C.
    Marinkovic, M.
    Bleeker, J. C.
    Jager, M. J.
    de Klein, A.
    van Doorn, R.
    Nielsen, M.
    ACTA OPHTHALMOLOGICA, 2018, 96 : 46 - 46
  • [48] BAP1 expression in cutaneous melanoma: a pilot study
    Murali, Rajmohan
    Wilmott, James S.
    Jakrot, Valerie
    Al-Ahmadie, Hikmat A.
    Wiesner, Thomas
    McCarthy, Stanley W.
    Thompson, John F.
    Scolyer, Richard A.
    PATHOLOGY, 2013, 45 (06) : 606 - 609
  • [49] Prognostic Factor Utility of BAP1 Immunohistochemistry in Uveal Melanoma: A Single Center Study in Spain
    Tabuenca Del Barrio, Laura
    Miguel Nova-Camacho, Luiz
    Zubicoa Eneriz, Alicia
    de Espronceda Ezquerro, Inigo Martinez
    Cordoba Iturriagagoitia, Alicia
    Borque Rodriguez-Maimon, Enrique
    Garcia-Layana, Alfredo
    CANCERS, 2021, 13 (21)
  • [50] SF3B1 and BAP1 mutations in blue nevus-like melanoma
    Griewank, Klaus G.
    Mueller, Hansgeorg
    Jackett, Louise A.
    Emberger, Michael
    Moeller, Inga
    van de Nes, Johannes A. P.
    Zimmer, Lisa
    Livingstone, Elisabeth
    Wiesner, Thomas
    Scholz, Simone L.
    Cosgarea, Ioana
    Sucker, Antje
    Schimming, Tobias
    Hillen, Uwe
    Schilling, Bastian
    Paschen, Annette
    Reis, Henning
    Mentzel, Thomas
    Kutzner, Heinz
    Ruetten, Arno
    Murali, Rajmohan
    Scolyer, Richard A.
    Schadendorf, Dirk
    MODERN PATHOLOGY, 2017, 30 (07) : 928 - 939
12345